We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-5.86%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.62B
AUM Growth
-$2.78B
Cap. Flow
-$2.47B
Cap. Flow %
-43.88%
Top 10 Hldgs %
56.27%
Holding
465
New
101
Increased
59
Reduced
84
Closed
204

Top Sells

Rank Stock Value
1
KVUE icon
Kenvue
KVUE
+$70.6M
2
IMVT icon
Immunovant
IMVT
+$56.5M
3
XRAY icon
Dentsply Sirona
XRAY
+$53.6M
4
GEHC icon
GE HealthCare
GEHC
+$53.1M
5
PTCT icon
PTC Therapeutics
PTCT
+$51.5M

Sector Composition

Rank Sector Weight
1 Healthcare 38.27%
2 Technology 7.29%
3 Consumer Discretionary 4.25%
4 Communication Services 1.58%
5 Consumer Staples 1.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RIGL icon
26
Rigel Pharmaceuticals
RIGL
$750M
$34.6M 0.62%
1,280,000
+444,000
+53% +$14.9M
IRON icon
27
Disc Medicine
IRON
$2.91B
$34.3M 0.61%
536,000
+36,609
+7% +$2.54M
GOOGL icon
28
Alphabet (Google) Class A
GOOGL
$4.23T
$34.1M 0.61%
118,514
-77,906
-40% -$24.5M
MLYS icon
29
Mineralys Therapeutics
MLYS
$2.39B
$31.9M 0.57%
1,176,000
+499,965
+74% +$14.7M
HUBS icon
30
HubSpot
HUBS
$11.5B
$31.4M 0.56%
128,583
+60,583
+89% +$17M
AXGN icon
31
Axogen
AXGN
$2.12B
$31M 0.55%
936,000
OFIX icon
32
Orthofix Medical
OFIX
$468M
$31M 0.55%
2,700,000
+52,000
+2% +$687K
KURA icon
33
Kura Oncology
KURA
$964M
$30.4M 0.54%
3,736,000
-1,200,000
-24% -$10.3M
AVNS icon
34
Avanos Medical
AVNS
$1.17B
$28M 0.5%
2,000,000
-1,200,000
-38% -$16.2M
REGN icon
35
Regeneron Pharmaceuticals
REGN
$70.9B
$27.9M 0.5%
36,126
-47,874
-57% -$36.7M
ALGN icon
36
Align Technology
ALGN
$12.7B
$27.1M 0.48%
157,959
+81,855
+108% +$14.3M
PTCT icon
37
CALL
PTC Therapeutics
PTCT
$6.52B
$26.6M 0.47%
+390,000
New +$27.6M
MDB icon
38
MongoDB
MDB
$25.1B
$26.3M 0.47%
107,296
+58,152
+118% +$19.5M
BABA icon
39
Alibaba
BABA
$276B
$25.6M 0.46%
204,000
-115,100
-36% -$17.3M
MDLN
40
Medline Inc
MDLN
$33.6B
$25.1M 0.45%
564,857
+506,841
+874% +$22.4M
KALV
41
DELISTED
KalVista Pharmaceuticals
KALV
$24.9M 0.44%
1,236,000
+436,000
+55% +$7.03M
DDOG icon
42
Datadog
DDOG
$92.1B
$24.6M 0.44%
208,564
-35,973
-15% -$4.44M
HUM icon
43
Humana
HUM
$48B
$24.5M 0.44%
141,279
+69,582
+97% +$14.3M
S icon
44
SentinelOne
S
$6.71B
$24.4M 0.43%
1,897,849
-524,370
-22% -$7.28M
VSTM icon
45
Verastem
VSTM
$530M
$24.3M 0.43%
4,592,000
+1,056,000
+30% +$6.51M
FIVN icon
46
FIVE9
FIVN
$1.96B
$24.2M 0.43%
1,592,000
-408,000
-20% -$7.09M
ISRG icon
47
Intuitive Surgical
ISRG
$122B
$24M 0.43%
52,043
-9,030
-15% -$4.57M
GRFS
48
Grifois
GRFS
$4.95B
$24M 0.43%
2,988,000
+220,000
+8% +$1.94M
PENN icon
49
PENN Entertainment
PENN
$2.75B
$23.7M 0.42%
1,578,000
-1,518,000
-49% -$21.1M
SLDB icon
50
Solid Biosciences
SLDB
$858M
$23M 0.41%
3,200,000
+588,000
+23% +$3.78M

Similar funds

Armistice Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Armistice Capital held 465 positions worth $5.62B, down 33% from $8.4B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital withdrew a net $2.47B in Q1 2026, closing 204 positions and reducing 84 holdings. Its most notable exit was argenx, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 33% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Armistice Capital opened a new position in UnitedHealth worth $40M.

  • Armistice Capital's largest Q1 2026 buy was UnitedHealth: 148,000 shares worth $40M.
  • Armistice Capital added most to Harmony Biosciences in Q1 2026, an estimated $36.9M increase.
  • Armistice Capital's biggest Q1 2026 reduction was Kenvue, cutting an estimated $70.6M.
  • Armistice Capital fully exited argenx in Q1 2026, selling an estimated $48.8M.
  • Armistice Capital's ten largest holdings make up 56% of its $5.62B portfolio in Q1 2026.
  • Armistice Capital opened 101 new positions and closed 204 in Q1 2026.
  • Armistice Capital's portfolio value fell 33% quarter-over-quarter to $5.62B.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.